Company Interview / Orthocell (ASX:OCC) Investor Presentation

Orthocell (ASX:OCC) is positioning itself at the forefront of regenerative medicine, focusing on collagen and cell therapies that support nerve and bone repair. Paul Anderson, Orthocell chief executive, highlights momentum from the launch of its flagship nerve repair product, Remplir, in the US—now the company’s central growth strategy. With approvals in 15 global jurisdictions, including Australia, Singapore, Hong Kong, and Thailand, and a strong manufacturing base in Australia, Orthocell aims to consolidate its global presence, particularly through expansion in the Americas and plans for entry into the EU and UK markets.

Anderson notes that Orthocell has experienced six consecutive quarters of record revenue growth, backed by a robust financial position with no debt and $51 million in cash following a recent $30 million capital raise. The company’s US strategy involves building distributor networks, securing state licenses, and training key medical opinion leaders, already resulting in active accounts across 25 states and rapid market traction. Remplir enjoys widespread use in Australia, showing strong uptake among surgeons and use in over 200 hospitals.

Looking ahead, Anderson outlines ambitions to extend Orthocell’s product portfolio, deepen clinical validation, and drive adoption in specialised areas such as nerve repair for radical prostatectomy procedures. With these developments, Orthocell targets ongoing revenue growth and increasing international market share.

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD